News

INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low
INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early ...
Healio4h
FDA accepts new drug application for sublingual epinephrine film
The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...
How weight-loss jabs like Mounjaro and Ozempic can destroy your pancreas. First the flesh dies... then your organs fail. As they're linked to ten deaths, doctors' urgent ...
The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...
Tyla16h
Doctors reveal early warning signs of life-threatening illness linked to weight loss jabs
These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...
Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin
Explore the latest on VYVGART HYTRULO's FDA safety signal and transition challenges. Learn why argenx's balanced risks keep ...
US FDA to revise ADHD stimulants labels to warn of weight loss risk in children under 6
The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...
US FDA to revise label of ADHD stimulants to add weight loss risk in patients younger than 6
The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants to treat ...
Inmune Bio Reports Key Findings From Phase 2 Mindful Trial Of Xprotm In Early Alzheimer's Disease
In the Phase 2 MINDFuL trial of XProTM in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat ...
Taiwan News14h
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus ...
Taiwan News14h
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Across both studies, the majority of treatment emergent adverse events (TEAEs) reported were mild to moderate and consistent with the known mechanism of action of felzartamab in the PMN population.